non prescription glp-1 Activator Is GLP-1 Safe for Weight

How to interpret the labs Reduced intake can change diabetes medication needs and dehydration risk

The trial found that after 5 years, Wegovy significantly reduced the risk of death from heart disease by 15% and reduced the risk of cardiovascular events including nonfatal heart attacks and strokes by 20%, compared to an inactive placebo

GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects

Furthermore, a systematic review of randomized controlled trials and observational studies also failed to identify an increased risk of aspiration pneumonia in GLP-1RA users, although an increased risk of retained gastric contents was evident (45)